Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Idorsia in the transaction. Idorsia Ltd (SIX:IDIA) announced that it entered into an agreement with Janssen Biotech Inc., one of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aspect Biosystems on the transaction. Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, and leading global...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Regor Therapeutics on the deal. Eli Lilly and Company and Regor Therapeutics Group entered into a multi-year research collaboration and...
You must be a Standard 1 Year member to access this content.
